Vaccinology - Vaccination in practice Flashcards

1
Q

What is the most important opportunity to lower the incidence of tropical diseases?

A

Improved education & hygiene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the causative agent of diphtheria?

A

Corynebacterium diphtheriae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What causes symptoms in diphtheria?

A

Diphtheria toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the symptoms of diphtheria? (6)

A
  1. Fever
  2. Swollen neck due to lymphadenopathy
  3. Dyspnoea due to swelling of the nasopharynx
  4. Cutaneous laesions
  5. Cardiac involvement
  6. Neurologica/muscle involvement (late stage)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How many % of diphtheria patients have cardiac involvement?

A

10-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How many % of children worldwide have been vaccinated against diphtheria?

A

90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How many children remain unvaccinated for diphtheria? Where are they primarily located?

A

~20 million, mostly in Africa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the WHO goal regarding diphtheria vaccination?

A

Making immunization available to everyone by 2030

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the challenges to increasing global vaccination coverage in low- and middle income countries (LMICs)? (7)

A
  1. Financial: lack of public funding
  2. Economic: low commercial viability -> vaccine shortages
  3. Logistical: cold chain
  4. Attitudes towards vaccines
  5. Political: conflict
  6. Other health-related problems
  7. Vaccine safety issues (immune-enhancement of disease, live vaccines)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are health-related reasons that prevent good vaccination coverage in low- and middle income countries (LMICs)? (3)

A
  1. AIDS
  2. Malnutrition
  3. AIDS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the challenges to increasing global vaccination coverage in high-income countries (HICs)? (7)

A
  1. Financial: budget travel
  2. Economic: low commercial viability -> shortages
  3. Logistical: lack of planning
  4. Attitudes: antivaxx
  5. Political: lack of insurance coverage
  6. Health: ageing
  7. Vaccine safety (immune-mediated enhancement of disease, live vaccines)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why is budget travel a problem for good vaccine coverage in high-income countries (HICs)?

A

Budget travellers don’t spend money on vaccinations to protect themselves against disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How was hepatitis A eradicated in high-income countries (HICs)?

A

Improving hygiene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the symptoms of hepatitis A? (6)

A
  1. Juandice
  2. Dark urine/pale stools
  3. Diarrhoea
  4. Nausea
  5. Vomiting
  6. Abdominal pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How many % of children have no symptoms during a hepatitis A infection?

A

80-95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the mortality of hepatitis A in adults?

A

2,1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the transmission route of hepatitis A?

A

Faecal-oral transmission through direct contact or food/water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the predictors of hepatis A infection? (3)

A
  1. Socio-economic status
  2. Household size
  3. Access to sanitation facilities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the adherence to vaccination guidelines of travellers?

A

~60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

There [is/isn’t] a hepatitis A vaccine available

A

There is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How many vaccine doses are required for hepatitis A? How long is the protection?

A

2 doses = 40 years protection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What determines the acceptable failure rate of vaccines? What is generally considered acceptable?

A

Acceptable failure rate depends on the pathogen
Generally 10-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the standard course of action upon vaccine failure?

A

Repeat vaccination schedule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

To which virus family does yellow fever belong?

A

Flavivirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How is yellow fever transmitted?

A

Aedes & Haemogogus mosquitos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How many % of yellow fever-infected individuals are symptomatic?

A

13-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are the symptoms of yellow fever?

A
  1. Red eyes
  2. Headache
  3. Jaundice
  4. Muscle ache
  5. Hepatomegaly
  6. Vomiting
  7. Back pain
  8. Haemorrhage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

How many % of symptomatic yellow fever-infected individuals become haemorrhagic?

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

How many % of haemorrhagic yellow fever patients die?

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are the laboratory characteritics of yellow fever? (3)

A
  1. High CRP
  2. High transaminases (ALAT/ASAT)
  3. Low thrombocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the treatment for symptomatic yellow fever?

A

Only symptomatic treatment available, no antivirals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the global incidence & mortality of yellow fever?

A

Incidence: 200.000/year
Mortality: 30.000/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Where do yellow fever cases primarily occur?

A

Around the equator in Africa & Asia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is the reservoir of yellow fever?

A

Non-human primates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Can yellow fever be eradicated?

A

No -> the animal reservoir makes it impossible to eradicate this disease (with current technology)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What are the possible transmission cycles of yellow fever? (3)

A
  1. Jungle
  2. Intermediate / savannah
  3. Urban
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the jungle transmission cycle of yellow fever?

A

Passed between non-human primates by mosquitos, incidental infection of humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the intermediate / savannah transmission cycle of yellow fever?

A

Hybrid transmission cycle, mosquitos pass the virus between humans & non-human primates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is the urban transmission cycle of yellow fever?

A

Passed between humans by mosquitos

40
Q

True or false: yellow fever can be transmitted from person-to-person

A

True, but: humans are very poor at transmitting yellow fever without mosquito vectors

41
Q

There [is/isn’t] a vaccine available for yellow fever

A

There is a good vaccine available

42
Q

How many doses of yellow fever vaccine are needed to protect an individual? How long does this protection last?

A

One dose = life-long protection

43
Q

What are the main problems of the yellow fever vaccine? (3)

A
  1. Shortages
  2. Live attenuated vaccine cannot be given to immunocompromised individuals, infants & elderly
  3. Rare vaccine complciations
44
Q

Who are the producer of the yellow fever vaccine?

A

Sanofi Pasteur

45
Q

What is the yearly available stock of yellow fever vaccine? How many doses are needed?

A

80 million available, 400 million needed

46
Q

What are the rare vaccine complications of yellow fever? (2)

A
  1. YEL-AND = neurological disease
  2. YEL-AVD = visceral disease
47
Q

What are the benefits of the live-attenuated yellow fever vaccine? (2)

A
  1. Induces long-lived memory responses
  2. Induces effective CD8+ effector and memory subsets
48
Q

What enables the live attenuated yellow fever vaccine to induce long-lived memory responses and CD8+ responses?

A
  1. Live attenuated vaccine spreads systemically -> induces a thorough immune response
  2. Live attenuated vaccine gives a longer antigen exposure -> enough time to develop a T-effector memory subset
49
Q

Which cells are mainly responsible for protection against yellow fever post-vaccination?

A

T-effector memory cells

50
Q

Why is a subunit vaccine not useful for yellow fever?

A

Does not induce the CD8+ T-cell memory subset necessary to defend against the virus

51
Q

What is the WHO goal regarding yellow fever?

A

Eliminate outbreaks by 2026

52
Q

How many % population immunity is required to prevent yellow fever outbreaks?

53
Q

To which virus family does dengue belong?

A

Flavivirus

54
Q

How many serotypes of dengue virus are there?

55
Q

What is the mode of transmission of dengue virus?

A

Aedes mosquitos

56
Q

What are the symptoms of mild dengue? (3)

A
  1. Rash
  2. Fever
  3. Muscle/joint pain
57
Q

What is the devere form of a dengue infection?

A

Dengue heamorrhagic fever syndrome

58
Q

Why are secondary, heterotypic dengue infections problematic?

A

They allow for antibody-dependent enhancement (ADE) of disease

59
Q

What is a ‘heterotypic infection’? (definition)

A

Infection by a different serotype of a virus you have previously been infected by

60
Q

What is the danger of dengue vaccines?

A

Can cause antibody-dependent enhancement (ADE) disease enhancement if the vaccine serotype differs from the infection serotype

61
Q

What is the effect of dengue vaccination of individuals that were seropositive for dengue prior to vaccination?

A

90% risk reduction by vaccine

62
Q

What is the effect of dengue vaccination of individuals that were seronegative for dengue prior to vaccination?

A

Protection for some times (~7 months), but 2x higher risk of symptomatic dengue after this period

63
Q

What is the effect of vaccine-induced ADE of dengue on global vaccine confidence?

A

A vaccination campaign in the Philippines greatly reduced global vaccine trust

64
Q

What is the mechanism of antibody-dependent enhancement (ADE) in dengue?

A

Antibodies against one serotype bind to other serotypes, but don’t neutralize the virus. The antibodies then form an entry point into macrophages due to Fc-mediated phagocytosis -> viral replication within the macrophage

65
Q

What is the solution to vaccine-induced antibody-dependent enhancement (ADE) in dengue?

A

Develop a vaccine that produces serotype-specific antibodies for all 4 serotpyes

66
Q

What is an important requirement of dengue vaccines aimed at preventing antibody-dependent enhancement of disease?

A

The serotype-specific antibodies really need to be unable to bind to other serotypes, to prevent forming an entry point into macrophages

67
Q

What is the most serotype-specific gene of dengue viruses? What is a downside of aiming for this gene?

A

Domain III of the envelope (E-)protein

Downside: not very immunogenic -> lot of adjuvants required

68
Q

What is the aim of the BCG vaccine?

A

Prevent miliary TB & TB meningitis (but not infection)

69
Q

What is the difficulty of evidence-based vaccination immunocompromised individuals?

A

Limited studies & heterogeneous population -> often no good evidence-based practices established

70
Q

Which strategy is often taken in the vaccination of immunocompromised individuals when there is no evidence-based strategy?

A

Eminence-based -> advice based on reasoning

71
Q

Vaccinations [are/are not] indicated in immunocompromised individuals

A

Immunocompromised individuals greatly benefit from any vaccine to boost & support their weak immune system. Caveat: no live attenuated vaccines

72
Q

Which type of vaccines is always contra-indicated in immunocompromised individuals?

A

Live (attenuated) vaccines

73
Q

What is a risk of vaccination of immunocompromised individuals?

A

It may in some instances lead to worsening of underlying disease

74
Q

Into which rough groups can immunocompromised individuals be grouped? (4)

A
  1. Compromised barrier function
  2. Primary immunodeficiencies
  3. Los of humoral immunity, not-being PID
  4. Loss of cellular immunity, not-being PID
75
Q

What are examples of instances of compromised barrier function that can lead to a weakened immune defence? (3)

A
  1. Use of antacids
  2. IBD
  3. Severe skin disease
76
Q

What are the consequences for vaccination of immunocompromised individuals due to compromised barrier function?

A

Relatively normal immunity -> can receive normal vaccinatinos
Addition advice: vaccination for Salmonella typhi when travelling to the tropics

77
Q

Which precaution should individuals with a compromised barrier function take before travelling to the tropics?

A

Salmonella typhi vaccine

78
Q

For which type of infections are individuals with a compromised barrier function especially susceptible?

A

GI-infections

79
Q

What is the advice regarding vaccination of individuals with severe primary B-lymphocyte disorders?

A

No live vaccines

80
Q

What are examples of severe primary B-lymphocyte disorders? (2)

A
  1. XLA
  2. T-B- SCID
81
Q

What is the advice regarding vaccination of individuals with less-devere primary IgA/IgG deficiencies?

A

No oral polio vaccine & varicella zoster vaccine, other vaccines are safe

82
Q

What is the advice regarding vaccination of individuals with primary T-lymphocyte disorders?

A

No live vaccines

83
Q

What is the downside of vaccination of individuals with primary T-lymphocyte disorders?

A

Vaccine efficacy of all vaccines severely reduced

84
Q

What is the advice regarding vaccination of individuals with primary complement disorders?

A

All vaccines are safe and strongly recommended to boost weakened immune system. Sometimes extra vaccines given.

85
Q

Which type of vaccine is especially recommended for individuals with primary complement disorders?

A

Polysaccharide vaccines

86
Q

What is the advice regarding vaccination of individuals with primary phagocytosis disorders?

A

No live bacterial vaccines, live-attenuated vaccines probably safe. All vaccines effective.

87
Q

What is the advice regadering vaccination of individuals with acquired loss of humoral immunity? (2)

A
  1. Follow the same rules as for primary B-cell disorders -> no live vaccines
  2. Check antibody titres post vaccination
88
Q

What are causes of acquired loss of humoral immunity? (3)

A
  1. B-cell or antibody-depleting therapies
  2. Loss of antibodies due to nephrotic syndrome or other causes
89
Q

What is the advice regadering vaccination of individuals with acquired loss of cellular immunity? (3)

A
  1. Follow the same rules as for primary T-cell disorders -> no live vaccines
  2. Give additional vaccines prior to/during therapy: VZV & pneumococcal
  3. Check titres post-vaccination
90
Q

What are causes of acquired loss of cellular immunity? (3)

A
  1. T-cell depleting therapies
  2. Malignancy
  3. HIV
91
Q

When does corticosteroid treatment count as mild immunosuppression?

A

<30 mg prednisone/day (or equivalent)

92
Q

When does corticosteroid treatment count as severe immunosuppression?

A

> 30 mg prednisone/day (or equivalent) for >14 days

93
Q

How long can the effect of severe immunosuppression by corticosteroids last?

A

Up to 3 months

94
Q

What determines the duration of recovery after severe immunosuppression by corticosteroids?

A

Higher dose/longer duration = longer recovery

95
Q

What is are the prednisone equivalents of 10 mg prednisone of 1. hydrocortisone, 2. methylprednisolone, 3. triamcinolone, 4. dexamethasone

A

10 mg prednisone =
1. 40 mg hydrocortisone (x4)
2. 8 mg methylprednisolone (x0,8 OR /1.25)
3. 8 mg triamcinolone (x0,8 OR /1.25)
4. 1,5 mg dexamethasone (x0,15 OR /6.66)